Tenaya Therapeutics, Inc.
TNYA
NASDAQ·Healthcare·Biotechnology·Mkt cap $148.3M
$0.68
▼ -1.74%
P/E
-2.36
Mkt Cap
$148.3M
52-Wk Range
$0.53–$2.35
52-Week Range
$0.53 - $2.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 51.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.8). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-6.2% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TNYA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 5, 2026
Reported EPS of -$0.20 vs -$0.07 consensus (-192.7% surprise). Revenue of $1.1M vs $10.0M expected (-88.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-192.7%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$225.0K
$1.1M
Margins · last 2Q
Gross
100.0%
Profit
-3909.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Chardan Capital · Mar 12, 2026
vs Industry
How TNYA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.